AI Summary
✦ ClarthaJFL Life Sciences is a healthcare company, but the provided information does not identify specific products or operating segments. Revenue grew 76.3% year-on-year, while profit increased 26.0%, indicating operating momentum without a disclosed event-driven catalyst. No major recent developments were reported. Margins are improving, although the slower profit increase versus revenue warrants monitoring for earnings-quality pressure. ROE and debt-to-equity data are unavailable, preventing assessment of capital efficiency and leverage. At 42.5 times earnings, the shares appear overvalued relative to the 26.0% profit-growth rate, leaving valuation exposed if growth moderates. Neutral sentiment reflects limited disclosure and the absence of a clear near-term catalyst.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 100 using growth durability 100.0.
Valuation
No valid valuation metrics were supplied.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 0 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Neutral. fundamentals provide support, while technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
Historical valuation metrics are unavailable for this ticker right now.
Peers & Comparison
Sector: Healthcare · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
LARSEN & TOUBRO LTD. LTPharmaceuticals | +8.1% | 5.6% | 33.5x Undervalued | -23% vs avg | +10.7% |
MANKIND PHARMA LIMITED MANKINDPharmaceuticals | +12.9% | 13.9% | 49.7x Premium | +15% vs avg | +0.3% |
GLENMARK PHARMACEUTICALS GLENMARKPharmaceuticals | +23.1% | 10.1% | 35.6x Undervalued | -18% vs avg | +9.4% |
ABBOTT INDIA LIMITED ABBOTINDIAPharmaceuticals | +6.5% | 22.4% | 37.6x Fair | -13% vs avg | -15.4% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 38.7x Fair | -11% vs avg | +30.0% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 38.8x Fair | -11% vs avg | +22.5% |
ZYDUS LIFESCIENCES LTD ZYDUSLIFEPharmaceuticals | +16.2% | 18.6% | 22.4x Undervalued | -48% vs avg | +17.1% |
LAURUS LABS LIMITED LAURUSLABSPharmaceuticals | +29.1% | 15.0% | 90.6x Premium | +109% vs avg | +123.1% |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹63 CrMar 2026Latest net profit
₹1.66 CrMar 2026Latest EPS
₹0.25Mar 2026Net margin
5.6%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 21.70 | 9.54 | 39.51 | 21.25 | 11.73 | 11.59 | 29.91 | 26.84 | 63.05 |
| Expenses + | 20.15 | 6.48 | 37.10 | 19.90 | 10.35 | 9.66 | 27.00 | 23.49 | 59.54 |
| Operating Profit | 1.55 | 3.06 | 2.41 | 1.35 | 1.38 | 1.93 | 2.91 | 3.35 | 3.51 |
| OPM % | 7.14% | 32.08% | 6.10% | 6.35% | 11.76% | 16.65% | 9.73% | 12.48% | 5.57% |
| Other Income + | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 |
| Interest | 0.09 | 0.26 | 0.27 | 0.20 | 0.33 | 0.24 | 0.44 | 0.38 | 1.03 |
| Depreciation | 0.11 | 0.24 | 0.24 | 0.16 | 0.36 | 0.26 | 0.27 | 0.27 | 0.27 |
| Profit before tax | 1.37 | 2.56 | 1.90 | 0.99 | 0.69 | 1.43 | 2.21 | 2.71 | 2.25 |
| Tax % | 13.14% | 25.39% | 23.16% | 25.25% | 86.96% | 48.25% | 10.86% | 25.09% | 26.22% |
| Net Profit + | 1.19 | 1.91 | 1.45 | 0.74 | 0.08 | 0.75 | 1.97 | 2.02 | 1.66 |
| EPS in Rs | 0.18 | 0.29 | 0.22 | 0.11 | 0.01 | 0.11 | 0.30 | 0.31 | 0.25 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Certificate under SEBI (Depositories and Participants) Regulations, 2018